Thumbnail Image
Publication

A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

Venugopal, B
; 
Baird, R
; 
Kristeleit, R
; 
Plummer, R
; 
Cowan, Richard A
; 
Stewart, A
; 
Fourneau, N
; 
Hellemans, P
; 
Elsayed, Y
; 
McClue, S
... show 7 more
Citations
Altmetric:
Abstract
To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).
Authors
Venugopal, B
Baird, R
Kristeleit, R
Plummer, R
Cowan, Richard A
Stewart, A
Fourneau, N
Hellemans, P
Elsayed, Y
McClue, S
Smit, J
Forslund, A
Phelps, C
Camm, J
Evans, T
de Bono, J
Banerji, U
Affiliation
University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow; The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust; UCL Cancer Institute; St. George's University of London, London; Northern Centre for Cancer Care, Freeman Hospital, Newcastle; The Christie NHS Foundation Trust, Manchester, United Kingdom; Janssen Research & Development, LLC, Beerse, Belgium; and Janssen Research & Development, LLC, Raritan, New Jersey.
Description
Date
2013-08-01
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
4262.full.pdf
Adobe PDF, 678.03 KB
Keywords
Type
Article
Citation
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. 2013, 19 (15):4262-72 Clin Cancer Res
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/302288
Embedded videos